Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.58

-1.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Arthur Radley	11/20/2004 8:51:42 PM
	Read Replies (2) of 52153

Is anyone following the developments in the new field of RNAi? On November 10th, Alnylam (ALNY)issued a PR claiming to be the first company to demonstrate in vivo that RNA Interference was a potential new treatment method to lower the expression of a clinically relevant target. I find this interesting since it appears that Sirna Therapeutics (RNAI) has published several articles and even presented data at numerous medical forums prior to this November event for (ALNY). Also it appears that with (ALNY) using an enormous dosing of 50 mg/kg as compared to (RNAI's) miniscule 3 to 5 mg/kg, (RNAI) obtained more positive data than (ALNY). (RNAI) got a 95% reduction in expression of green fluorescent protein in the liver for up to 22 days from a single dosing in a transgenic mouse expressing green fluorsescent protein, compared to only 68% reduction achieved by (ALNY) using three doses that were 10 times higher. Appears we might have a patent fight on our hands, that is if this new approach has merit and is worth the litigation expense. Barron's has a very positive article today about (ALNY), but they never mention (RNAI). IMO it seems that (RNAI) is the one to follow. Any comments?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next